Geneva, May 4 -- International Clinical Trials Registry received information related to the study (ChiCTR2600123297) titled 'A single-dose and multiple-dose escalation study to evaluate the safety, tolerability, and pharmacokinetics of EVO756 in healthy Chinese participants' on April 23.

Study Type: Interventional study

Study Design: Parallel

Primary Sponsor: Peking University First Hospital

Condition: Chronic Spontaneous Urticaria

Intervention: Experimental group:Cohort1: 50 mg of EVO756 given as one 50 mg tablet, orally. study drug will be administered once on Day 1 and once daily on Days 3 through 9. Cohort2: 50 mg of EVO756 given as one 50 mg tablet, orally. study drug will be administered once on Day 1, twice daily on Days ...